Description
Indinol Forto Pharmacodynamics
Indinol® Forto is a universal corrector of pathological hyperplastic processes in the breast tissue. The therapeutic effect of Indinol® Forto is based on its anti-estrogenic and antiproliferative effect. The main property of indolecarbinol (intrinol) is its ability to induce selective death of breast cells with abnormally high proliferative activity.
Indolcarbinol modulates the cytochrome system so that the resulting cytochrome P450-CYP1A1 isoform hydroxylates estrogens at the 2nd position to form 2-hydroxyestrone (2-OHE1). The resulting metabolite is an estrogen receptor antagonist and blocks its activation by estrogens themselves as well as their dangerous metabolites, particularly 16-alpha-hydroxyestrone (16?-OHE1), whose proportion among metabolites is reduced. In this way, the induction of estrogen-dependent genes is suppressed, and the cell ceases to receive excessive estrogen-dependent stimulation. Indolcarbinol also blocks other signaling mechanisms (cytokines) that stimulate pathological cell growth in the breast tissue by inhibiting the signaling cascades from the corresponding receptors.
A course of treatment with the drug promotes reduction of intensity and disappearance of pain syndrome in the breast at cyclic mastalgia (mastodynia).
Use of the drug Indinol® Forto does not lead to weight gain
Indinol® Forto is practically non-toxic (LD50>5 g/kg).
Indications
Cyclic mastalgia, also against the background of benign breast hyperplasia
Contraindications
The drug is contraindicated in case of any of the following conditions
Hypersensitivity to indolcarbinol or any of the drug’s excipients.
Hereditary lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Pregnancy and breast feeding period.
Childhood age under 18 years old.
Administration during pregnancy and breast-feeding:
The use of the drug Indinol® Forto is contraindicated during pregnancy and breastfeeding.
Dosage and administration method
- Orally, twice a day in dose 200 mg.
- The daily dose is 400 mg.
- The capsules are taken before meals.
- The duration of treatment course is 6 months.
